At Apotex, our litigation efforts have ultimately been about advocacy. We have helped bring over 20 drugs to market before patent expiry in the past 5 years alone.

Our investments and efforts to launch products before patent expiry have saved public and private payers over $4 billion in the last 5 years alone. These savings have ultimately benefited the Canadian Healthcare system, as that money can then be used in other areas of need, ultimately benefiting all our stakeholders.

Drugs Brought to Market Pre-Patent Expiry (2010 to 2015)

* Size of bubble represents brand sales prior to generic launch.

2010

Apo-Atorvastatin (LIPITOR®)
# of years launched prior to patent expiry: 12
$1,201,183,981 brand value

Apo-Tramadol/Acetaminophen (TRAMACET®)
# of years launched prior to patent expiry: 2.5
$26,463,554 brand value

Apo-Dorzolomide/Timolol (COSOPT®)
# of years launched prior to patent expiry: 1.5
$30,038,140 brand value

2011

Apo-Esomeprazole (NEXIUM®)
# of years launched prior to patent expiry: 8.7
$273,328,462 brand value

Apo-Latanoprost (XALATAN®)
# of years launched prior to patent expiry: 2.8
$41,406,464 brand value

Apo-Clopidogrel (PLAVIX®)
# of years launched prior to patent expiry: 7.5
$304,000,000 brand value

2012

Apo-Rosuvastatin (CRESTOR®)
# of years launched prior to patent expiry: 8
$742,164,006 brand value

Apo-Lamivudine (3TC®)
# of years launched prior to patent expiry: 3.8
$5,497,803 brand value

Apo-Lamivudine/Zidovudine (COMBIVIR®)
# of years launched prior to patent expiry: 3.7
$12,032,797 brand value

Apo-Lamivudine (HEPTOVIR® )
# of years launched prior to patent expiry: 3.5
$6,496,000 brand value

Apo-Riluzole (RILUTEK®)
# of years launched prior to patent expiry: 1.3
$4,460,000 brand value

2013

Apo-Quinapril (ACCUPRIL®)
# of years launched prior to patent expiry: 5.5
$30,000,000 brand value

Apo-Valganciclovir (VALCYTE®)
# of years launched prior to patent expiry: 2
$11,000,000 brand value

Apo-Olopatadine (PATANOL®)
# of years launched prior to patent expiry: 2.4
$12,400,000 brand value

Apo-Quinapril/HCTZ (ACCURETIC®)
# of years launched prior to patent expiry: 5.4
$16,000,000 brand value

2014

Apo-Voriconazole (VFEND®)
# of years launched prior to patent expiry: 4.5
$14,525,000 brand value

Mya (YAZ®)
# of years launched prior to patent expiry: 7.5
$15,259,000 brand value

Tricira Lo (ORTHO TRI-CYCLEN® LO)
# of years launched prior to patent expiry: 7.5
$23,523,000 brand value

Apo-Mycophenolic Acid (MYFORTIC®)
# of years launched prior to patent expiry: 3.7
$31,806,000 brand value

Apo-Adefovir (HEPSERA®)
# of years launched prior to patent expiry: 4
$3,642,000 brand value

Apo-Travoprost Ophthalmic Solution (TRAVATAN® Z)
# of years launched prior to patent expiry: 13
$22,562,000 brand value

Apo-Clarithromycin XL (BIAXIN XL®)
# of years launched prior to patent expiry: 3.5
$30,163,000 brand value

2015

Apo-Gliclazide (DIAMICRON® MR)
# of years launched prior to patent expiry: 13
$12,037,000 brand value

Apo-Tadalafil PAH (ADCIRCA®)
# of years launched prior to patent expiry: 5
$6,981,000 brand value

Through our ongoing aggressive product launch strategies, we will continue to bring challenging generic products and litigation-based launches to market sooner, driving needed savings to the Healthcare system.